<DOC>
	<DOC>NCT02412111</DOC>
	<brief_summary>This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.</brief_summary>
	<brief_title>A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Heterozygous for F508delCFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height during screening Stable CF disease as judged by the investigator. History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. Pregnant and nursing females (females of childbearing potential must have a negative pregnancy test at Screening and Week 4 Visits). Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>